Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Victor Sapena"'
Autor:
Angeles Garcia-Criado, Jordi Rimola, Susana Seijo, Anna Darnell, Ernest Belmonte, Victor Sapena, Julián Moreno-Rojas, Valeria Pérez, Virginia Hernández-Gea, Carmen Ayuso, Maria Reig, Juan Carlos Garcia-Pagan, Jordi Bruix
Publikováno v:
Liver Cancer (2023)
Introduction The incidence of hepatocellular carcinoma (HCC) in Budd-Chiari syndrome (BCS) is unknown and there is no validated diagnostic work-up to define the liver nodules with arterial phase hyperenhancement (APHE) suggesting malignancy. This pro
Externí odkaz:
https://doaj.org/article/813f99e541e045f9a8aa41600680637f
Autor:
Anna Soria, Mariona Calvo, Meritxell Casas, Zara Vidales, Sergio Muñoz-Martínez, Victor Sapena, Marc Puigvehi, Lidia Canillas, Raquel Guardeño, Adolfo Gallego, Beatriz Mínguez, Diana Horta, Ariadna Clos, Silvia Montoliu, Mercè Roget, Maria Reig, Mercedes Vergara
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionThe first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little evidence of efficac
Externí odkaz:
https://doaj.org/article/ee56ec9457554833bfaf62de8c746951
Autor:
Sergio Muñoz-Martínez, Victor Sapena, Ángeles García-Criado, Anna Darnell, Alejandro Forner, Ernest Belmonte, Marco Sanduzzi-Zamparelli, Jordi Rimola, Alexandre Soler, Neus Llarch, Gemma Iserte, Ezequiel Mauro, Carmen Ayuso, Jose Rios, Jordi Bruix, Ramon Vilana, María Reig
Publikováno v:
Cancers, Vol 15, Iss 13, p 3269 (2023)
Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients’ outcomes after recurrence. The present study evaluates the impact of patient
Externí odkaz:
https://doaj.org/article/b7fc947808234c3ca012bbb28c8f01b2
Autor:
Pablo Fernández-Tussy, Rubén Rodríguez-Agudo, David Fernández-Ramos, Lucía Barbier-Torres, Imanol Zubiete-Franco, Sergio López de Davalillo, Elisa Herraez, Naroa Goikoetxea-Usandizaga, Sofia Lachiondo-Ortega, Jorge Simón, Fernando Lopitz-Otsoa, Virginia Gutiérrez-de Juan, Misti V. McCain, Maria J. Perugorria, Jon Mabe, Nicolás Navasa, Cecilia M. P. Rodrigues, Isabel Fabregat, Loreto Boix, Victor Sapena, Juan Anguita, Shelly C. Lu, José M. Mato, Jesus M. Banales, Erica Villa, Helen L. Reeves, Jordi Bruix, Maria Reig, Jose J. G. Marin, Teresa C. Delgado, María L. Martínez-Chantar
Publikováno v:
Cell Death and Disease, Vol 12, Iss 6, Pp 1-16 (2021)
Abstract Dysregulation of miRNAs is a hallmark of cancer, modulating oncogenes, tumor suppressors, and drug responsiveness. The multi-kinase inhibitor sorafenib is one of the first-line drugs for advanced hepatocellular carcinoma (HCC), although the
Externí odkaz:
https://doaj.org/article/fb7ef154614446039d3b36ccb14472c8
Autor:
Valentina Cossiga, Marco Sanduzzi-Zamparelli, Victor Sapena, Maria Guarino, Marcello Dallio, Emanuele Torrisi, Luca Pignata, Alessandro Federico, Federico Salomone, Filomena Morisco
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Introduction and Aims: HCV eradication by direct-acting antivirals (DAAs) improves liver outcomes and reduces overall liver mortality. However, patients with advanced chronic liver disease (ACLD) may experience a progression of liver disease despite
Externí odkaz:
https://doaj.org/article/9786bfa428e247729e34d8ab7d697412
Autor:
Sergio Muñoz-Martínez, Victor Sapena, Alejandro Forner, Jean-Charles Nault, Gonzalo Sapisochin, Lorenza Rimassa, Bruno Sangro, Jordi Bruix, Marco Sanduzzi-Zamparelli, Wacław Hołówko, Mohamed El Kassas, Tudor Mocan, Mohamed Bouattour, Philippe Merle, Frederik J.H. Hoogwater, Saleh A. Alqahtani, Helen L. Reeves, David J. Pinato, Emmanouil Giorgakis, Tim Meyer, Gerda Elisabeth Villadsen, Henning Wege, Massimiliano Salati, Beatriz Mínguez, Giovan Giuseppe Di Costanzo, Christoph Roderburg, Frank Tacke, María Varela, Peter R. Galle, Mario Reis Alvares-da-Silva, Jörg Trojan, John Bridgewater, Giuseppe Cabibbo, Christian Toso, Anja Lachenmayer, Andrea Casadei-Gardini, Hidenori Toyoda, Tom Lüdde, Rosanna Villani, Ana María Matilla Peña, Cassia Regina Guedes Leal, Monica Ronzoni, Manuel Delgado, Christie Perelló, Sonia Pascual, José Luis Lledó, Josepmaria Argemi, Bristi Basu, Leonardo da Fonseca, Juan Acevedo, Alexander R. Siebenhüner, Chiara Braconi, Brandon M. Meyers, Alessandro Granito, Margarita Sala, Carlos Rodríguez-Lope, Lorraine Blaise, Manuel Romero-Gómez, Federico Piñero, Dhanny Gomez, Vivianne Mello, Rogerio Camargo Pinheiro Alves, Alex França, Fernanda Branco, Giovanni Brandi, Gustavo Pereira, Susanna Coll, Maria Guarino, Carlos Benítez, Maria Margarita Anders, Juan C. Bandi, Mercedes Vergara, Mariona Calvo, Markus Peck-Radosavljevic, Ignacio García-Juárez, Vincenzo Cardinale, Mar Lozano, Martina Gambato, Stefano Okolicsanyi, Dalia Morales-Arraez, Alessandra Elvevi, Alberto E. Muñoz, Alberto Lué, Massimo Iavarone, Maria Reig
Publikováno v:
JHEP Reports, Vol 3, Iss 3, Pp 100260- (2021)
Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening o
Externí odkaz:
https://doaj.org/article/358015dbb4fa490089fab9515bd56c57
Autor:
Josep Corominas, Victor Sapena, Marco Sanduzzi-Zamparelli, Cristina Millán, Esther Samper, Neus Llarch, Gemma Iserte, Ferràn Torres, Leonardo G. Da Fonseca, Sergio Muñoz-Martínez, Alejandro Forner, Jordi Bruix, Loreto Boix, María Reig
Publikováno v:
Cancers, Vol 13, Iss 3, p 426 (2021)
Advanced hepatocellular carcinoma patients treated with sorafenib who develop early dermatologic adverse events (eDAEs) have a better prognosis. This may be linked to immune mechanisms, and thus, it is relevant to assess the association between perip
Externí odkaz:
https://doaj.org/article/270dc578951d4a479b8e22602199b23c
Autor:
Reig, Sergio Muñoz-Martínez, Victor Sapena, Ángeles García-Criado, Anna Darnell, Alejandro Forner, Ernest Belmonte, Marco Sanduzzi-Zamparelli, Jordi Rimola, Alexandre Soler, Neus Llarch, Gemma Iserte, Ezequiel Mauro, Carmen Ayuso, Jose Rios, Jordi Bruix, Ramon Vilana, María
Publikováno v:
Cancers; Volume 15; Issue 13; Pages: 3269
Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients’ outcomes after recurrence. The present study evaluates the impact of patient
Autor:
Marco Sanduzzi-Zamparelli, Loreto Boix, Maria Reig, Alejandro Forner, Carmen Ayuso, Gemma Iserte, Victor Sapena, Ernest Belmonte, Sergio Muñoz-Martínez, Cassia Guedes, Anna Darnell, Ferran Torres, Jordi Bruix, Leonardo G Da Fonseca, Jordi Rimola, Neus Llarch, Álvaro Díaz-González
Publikováno v:
United European Gastroenterology Journal
Background Despite atezolizumab and bevacizumab (A + B) is currently the first‐line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have
Autor:
Aina Capdevila-Reniu, Margarita Navarro-López, Cristina Sierra-Benito, Victor Sapena, Ana Suárez-Lombraña, Bryan David Solari, Marta Arroyo, Miguel Camafort-Babkowski, Alfonso López-Soto
Background: Osteoporosis and cardiovascular diseases share risk factors and pathophysiological mechanisms. Hip fracture and cardiovascular diseases are very common in older people. Objectives: Evaluate clinical and subclinical arteriosclerotic diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be1548709bf65952d367a325865c3829
https://doi.org/10.21203/rs.3.rs-2085949/v1
https://doi.org/10.21203/rs.3.rs-2085949/v1